Sales & Marketing Evolving HCP access requires a new connected approach to bui... Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.
R&D In conversation with Chris Moore: Declining HCP access During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
Market Access Shifting HCP access calls for new field tactics globally Even before COVID-19 pushed access to an all-time low, access had been declining
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face